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Cortisol as an Acute Stress Biomarker in Young
Hematopoietic Cell Transplant Patients/Caregivers:
Active Music Engagement Protocol
Kristen A. Russ, PhD,1 Steven J. Holochwost, PhD,2 Susan M. Perkins, PhD,3,4
Kristin Stegenga, PhD, RN, CPON,5 Seethal A. Jacob, MD, MS, FAAP,3,6 David Delgado, MD,7
Amanda K. Henley, MM, MT-BC,8 Joan E. Haase, PhD, RN, FAAN,8 and Sheri L. Robb, PhD, MT-BC8
Abstract

Objective: Primary aims of the proposed protocol are to determine the feasibility/acceptability of the active
music engagement intervention protocol during hematopoietic stem cell transplantation (HSCT) and clinical
feasibility/acceptability of the biological sample collection schedule.
Design: The authors propose a single-case, alternating treatment design to compare levels of child and
caregiver cortisol in blood and saliva collected on alternating days, when the dyad receives and does not receive
AME sessions. Included are the scientific rationale for this design and detailed intervention and sample collection schedules based on transplant type.
Setting/Location: Pediatric inpatient HSCT unit.
Subjects: Eligible participants are dyads of children 3–8 years old, hospitalized for HSCT, and their caregiver. Children with malignant and nonmalignant conditions will be eligible, regardless of transplant type.
Intervention: AME intervention is delivered by a board-certified music therapist who tailors music-based
play experiences to encourage active engagement in, and independent use of, music play to manage the interrelated emotional distress experienced by children and their caregivers during HSCT. Dyads will receive two
45-min AME sessions each week during hospitalization.
Outcome Measures: Eight collections of blood (child) and saliva (child/caregiver) will be performed for cortisol
measurement. The authors will also collect self-report and caregiver proxy measures for dyad emotional distress,
quality of life, and family function. At study conclusion, qualitative caregiver interviews will be conducted.
Results: Planned analyses will be descriptive and evaluate the feasibility of participant recruitment, cortisol
collection, planned evaluations, and AME delivery. Analysis of qualitative interviews will be used to gain an
understanding about the ease/burden of biological sample collection and any perceived benefit of AME.
Conclusions: Behavioral intervention studies examining biological mechanisms of action in pediatric
transplant populations are rare. Findings will provide important information about the feasibility/acceptability
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of collecting cortisol samples during a high-intensity treatment and advance understanding about the use of
active music interventions to mitigate child/caregiver distress during the transplant period.
Keywords: biomarker, cortisol, stress, music therapy, pediatric, hematopoietic stem cell transplant
Introduction

H

ematopoietic stem cell transplantation (HSCT) is the
curative therapy of choice for many malignancies that
require high-dose chemotherapy, and sometimes radiation
therapy, and the only curative therapy option for some nonmalignant conditions such as hemoglobinopathies.1 Regardless of diagnosis, HSCT is an intense complex treatment with
many risks. Young children undergoing HSCT and their
caregivers are at particular risk for heightened emotional
distress, which is associated with physical symptom distress
and diminished quality of life and family function.2–9 In
addition, this acute emotional distress is related to traumatic
stress symptoms after treatment ends.8,10–15 Despite evidence
that young child and caregiver distress is inter-related, few
interventions have been developed to address this shared
distress3,8,9,13,16,17 and fewer specific to transplants.18
The active music engagement intervention uses music play
experiences to diminish stressful qualities of the treatment
environment, encouraging engagement and the use of positive coping strategies to reduce the emotional/traumatic distress experienced by young children (ages 3–8 years) and
caregivers and improve quality of life.19–21 Early studies
established AME as beneficial in managing child emotional
distress19–21 and explored caregiver benefit.21 The aim of the
current R01 mechanistic trial (NR015789) is to identify behavioral, sociological, and psychological variables that contribute to positive health outcomes observed in early AME
studies. To date, the authors’ studies have focused on short
inpatient admissions for chemotherapy and identification of
psychosocial mechanisms of action. In this study, the authors
will explore the feasibility/acceptability of AME during the
acute phase of HSCT, which is a high-intensity treatment
requiring 3–6 weeks of hospitalization. In addition, to expand
the understanding about how active music interventions work
to mitigate transplant-related stress, the authors will also
explore the feasibility/acceptability of collecting the stress
biomarker, cortisol, from children and caregivers.
Evidence that increased hypothalamic–pituitary–adrenal
(HPA) axis activity stimulates the release and production of
inflammatory biomarkers, which in turn is associated with
negative health outcomes for individuals undergoing treatment for chronic conditions and caregivers, supports investigation of biological pathways underlying the use of active
music to mitigate transplant-related stress.22–24 Cortisol is a
steroid hormone secreted by the HPA axis in response to
acute and prolonged stress, and assaying various bodily fluids
for cortisol is a widely used method of indexing HPA axis
activity in children.25 To date, few intervention studies have
looked at cortisol in pediatric patients with malignant and
nonmalignant conditions,26–28 and of those, only one used
music28 and none involved children and caregivers.26–28 This
is likely due to challenges associated with cortisol collection
and interpretation during cancer and HSCT treatment and
difficulties conducting fully powered, randomized intervention trials in low-incidence populations.29–31 To overcome

these challenges, the authors propose a single-case design
study, which allows for estimation of intervention effects in
small samples drawn from low-incidence populations.
The authors’ primary aims are to determine the feasibility/acceptability of the AME intervention protocol during
HSCT and evaluate clinical feasibility/acceptability of the
schedule for biological samples required when using a singlecase design. If the authors meet feasibility thresholds for blood
and salivary cortisol (collection and sample quantity/quality),
they will examine changes in parent and child cortisol levels
relative to the AME intervention. The secondary aim is to
examine the feasibility of completing self-report measures
used in prior AME studies in the context of HSCT. This
secondary aim will also establish whether it is feasible/acceptable to collect both biological and self-report data during a
high-intensity treatment in subsequent trials. Areas of evaluation include activities/timelines related to recruitment, blood
and salivary cortisol collection, planned evaluations, and intervention delivery. Specific research questions are as follows:
(1) What percentage of eligible child/caregiver dyads
consent to study participation?
(2) What percentage of AME sessions do child/caregiver
dyads complete?
(3) What percentage of planned measures [other than
cortisol] do caregivers complete?
(4) What percentage of planned cortisol samples are
collected and what percentage of these samples yield
usable data?
(5) What are caregivers’ perspectives about the relative
ease/burden of biological sample collection, benefit
(or nonbenefit) of AME for managing distress, and
enhancing family and quality of life outcomes for self
and child?
Materials and Methods
Conceptual framework

The conceptual framework (Fig. 1) is based on Robb’s
Contextual Support Model of Music Therapy19,32,33 and
further informed by Kazak’s Pediatric Medical Traumatic
Stress Model, which provides a useful heuristic for understanding short- and long-term consequences of HSCT
treatment for children and caregivers.4 In this framework,
recurring events related to HSCT (i.e., hospitalization,
symptom distress, and procedures) are viewed as potentially
traumatic events. Caregiver appraisal of events as traumatic
or not traumatic is influenced by pre-existing factors, which
serve as antecedents. Research indicates that higher child
and caregiver distress during HSCT is related to (1) demographics (younger child/caregiver age, female caregiver
gender, and lower socioeconomic status/education),34,35
(2) higher caregiver/child distress with prior hospitalizations and greater traumatic stress symptoms,2,36,37 and (3)
disease and treatment characteristics (diagnosis and transplant type).5,12,14,15,38
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FIG. 1. Conceptual framework. AME, active music engagement; ESAS, Edmonton Symptom Assessment System;
PCL-S, PTSD checklist; PIES, Prior Illness Experiences Scale.
The AME is designed to directly target potential proximal
mediators of child engagement and caregiver–child interaction,19,21 as well as distal mediators of perceived family
normalcy,39 caregiver confidence (self-efficacy) about their
ability to support their child during treatment,40 and independent music play between therapist-led sessions. Outcomes include child outcomes (emotional distress, physical
symptom distress, cortisol, and quality of life), caregiver
outcomes (emotional distress, traumatic stress symptoms,
cortisol, and quality of life), and family function.
Study design and rationale

In this one-group pilot study (Fig. 2), approved by the
Indiana University Institutional Review Board, children and
their caregivers will receive two 45-min AME sessions each
week during the acute phase of HSCT until time of discharge (i.e., two sessions/week for duration of treatment).
Session frequency and duration were selected based on
preliminary studies and HSCT symptom trajectory.19–21,41
The total number of sessions will be based on the individual
child’s admission period to account for variations in treatment duration, to mimic standard care, and to avoid removal
of AME as a supportive care service before discharge when
children and caregivers still require support. The authors
anticipate that a majority of patients will receive six sessions, over a 3-week period, and to collect data on the
number of sessions each dyad receives to inform analysis
and interpretation of findings.
Single-case designs were developed to facilitate examination of treatment when data can only be collected from a

small number of individuals, such as when investigating
different approaches to behavior modification among individuals with rare developmental disabilities.42 Using the
single-case alternating treatment design, the authors compare levels of cortisol in blood and saliva samples collected
from dyads on days when they receive AME sessions with
levels of cortisol on days when they do not receive AME.
Since relatively few children receive HSCT, the single-case
design is ideal for evaluating interventions during transplants.43 The essential logic of the single-case design, as
implemented in this study, is that levels of cortisol will be
consistently and clearly lower on days when dyads receive
AME than on days when they do not. If the analyses, as
described below, reveal that this is the case, the authors may
infer that AME caused observed reductions in cortisol.44
Participants and recruitment

Children/caregivers will be study eligible if the child (1)
is 3–8 years of age (inclusive) at the time of enrollment; (2)
will receive inpatient HSCT for a malignant or nonmalignant condition, including hemoglobinopathies; and (3) has
one caregiver who agrees to be present for all sessions.
Children/caregivers will not be eligible if (1) the caregiver or
child does not speak English or (2) if the child has a significant cognitive impairment that may hinder their ability
to participate, as determined by consultation with the attending HSCT physician, primary hematologist–oncologist,
and caregivers. Eligibility will not be dependent on transplant type (autologous or allogeneic).
The authors will enroll children, ages 3–8 years, admitted
for HSCT and one caregiver (i.e., parent or legal guardian)
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as dyads. The targeted sample size is four child–caregiver
dyads, which will provide the information needed to determine the feasibility/acceptability of study procedures and
refine intervention content. Certified research coordinators
will use an eligibility checklist to identify potential participants, and a study team member will provide study information, verify eligibility, and obtain written caregiver
consent/assent for children ‡7 years.

FIG. 2.

Study schema.

Active music engagement intervention

Dyads will receive two 45-min AME sessions in private
rooms at the HSCT unit each week for the duration of their
inpatient stay. AME sessions were designed for delivery by a
board-certified music therapist (MT-BC) who tailors musicbased play experiences to encourage active engagement in
and independent use of music play as a strategy to manage
distress.19–21 During sessions, the MT-BC provides dyads
repeated opportunities to experience competence, autonomy,
and meaningful interactions through music-based play activities and provides support/education about ways that children/caregivers can use music play to manage distress and
sustain a sense of family normalcy while being hospitalized
and following HSCT discharge. AME has three primary
components: (1) therapist-led music-based play activities and
sessions, (2) a music play resource kit (to promote independent music play), and (3) session planning and caregiver tip
sheets that focus on ways to use music play during hospitalization and as dyads transition from hospital to home
(Table 1).
Biological sample collection

The authors developed two sampling schedules based on
transplant type (Figs. 3 and 4) to address differences in
conditioning treatment protocols for autologous and allogeneic transplants and to avoid periods of treatment with
corticosteroids, which can interfere with cortisol measurements. Biological samples collected will include blood
(child) and saliva (child and caregiver). Blood (1 mL) will
be collected from the child’s central line as part of daily
transplant laboratories (drawn 4–6 am). The blood, in rapid
serum tubes, will be sent immediately to the pathology
laboratory for cortisol analysis using a Beckman Coulter
UniCel DxI800 immunoassay system. Saliva will be collected from the child and caregiver by study staff at three
different time points on each collection day: (1) up to 1 h
before the AME session, (2) up to 1 h after the session, and
(3) 1–3 h after the second collection. To collect saliva, the
child and caregiver will be instructed to drool into 50-mL
conical tubes until *500 mL of saliva is collected. The saliva will be immediately stored on dry ice and transferred to
-80C until analysis. Salivary cortisol levels will be measured using an R&D Systems cortisol parameter assay. For
child participants, the authors will capture medical record
data on any medications that can affect cortisol levels. In
addition, caregivers will complete a questionnaire (for self
and child) about activities or substances known to affect
cortisol levels (e.g., sleep, exercise, and caregiver medications) and timings/details of food intake.45
For this single-case design, the authors will also collect
biological measures on treatment and nontreatment days,
controlling for time of day (to account for daily fluctuations
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Table 1. Active Music Engagement Intervention Components and Theoretical Principles
Intervention component

Theoretical principles

Component 1: Music-Based
Play Activities

(1) Predictable environment provides a structure that supports child competence.
Therapist uses familiar music activities to provide structure and increase child’s ability to
predict what will happen in their environment.
(2) Leveled activities help ensure success and support child competence.
Therapist tailors physical activity requirements to meet the individual needs of each child.
Enables child success and engagement during periods of high or fluctuating symptom
distress.
(3) Opportunities to make independent decisions support child autonomy.
Children choose from a variety of music play activities, and each activity includes a wide
range of materials. Activities include a wide range of materials and activity options so
that the child can make choices for self and others.
Therapist uses improvisational techniques to follow child-initiated changes in their music
making (e.g., child changes tempo or style of playing).
(4) Activities structured to support caregiver–child interaction.
Activities structure and support reciprocal caregiver–child interactions. The therapist
individualizes experiences to support increased frequency and quality of interactions.
Component 2: Music Play
Supports independent use of music play to manage distress between therapist-led
Resource Kit
sessions.
Activities mirror content from therapist-led sessions. The kit includes:
(1) Professional CD recording of music composed and/or arranged specifically for the
AME intervention.
(2) Age-appropriate musical instrument and play materials that correspond to each
activity.
(3) Activity cards designed to give children/caregivers at-a-glance information on ways
they can use their kit.
Component 3: Session Planning (1) Promotes caregiver competence about how children use play to cope and ways to
and Caregiver Tip Sheets
engage their child in music play during the transplant period.
(2) Promotes caregiver autonomy by empowering caregivers with skills/resources to
support their child during treatment.
(3) Supports caregiver–child relationships through normalizing music-based play
activities.
AME, active music engagement.

in cortisol) and potential order effects. As seen in Figure 3,
the sampling schedule for autologous transplants includes
eight collections (4 treatment days and 4 control days).
The first four collections occur during conditioning for the
transplant; and the remaining four occur poststem cell
infusion. Note that the first collection serves as the
baseline for autologous participants. Treatment and control
days are linked (they occur 1 day apart and take place at the
same time of day), with four linked collections scheduled
over the course of the transplant.
The sampling schedule for allogeneic transplants (Fig. 4)
is similar; however, the timing of collection is adjusted to
account for drug interference that occurs during conditioning. Because allogeneic collections occur later in treatment,
the authors will collect baseline blood samples during a
routine clinic visit 1 week before admission. In addition,
before side effects (e.g., mucositis) occur, the authors will
schedule two practice collections to help children learn how
to give saliva samples. In both transplant regimens, the
number of collections exceeds the recommended number of
three data points per condition established for single-case
designs.46
Caregiver report measures

Caregivers will complete self-report and caregiver proxy
questionnaires at four time points (Table 2). Baseline mea-

sures will be completed during a routine clinic visit, within
30 days of the child’s scheduled HSCT admission. Time 2
measures will be completed post-AME session eight, Time 3
measures at the time of discharge (if discharge did not occur
at time of session eight), and Time 4 measures at 100 days
post-transplant during a subsequent clinic visit. In addition,
caregivers will complete brief pre/postsession measures for
caregiver distress/child symptom distress at sessions 2, 4,
and 6. All measures will be administered by trained evaluators not involved with AME delivery, and all evaluation
sessions audio-recorded for quality assurance monitoring.
The authors selected questionnaires based on the study’s
theoretical framework (Fig. 1), with careful consideration of
psychometric properties, sensitivity to change, and response
burden. Table 2 provides a list of all measures, including
psychometrics and administration schedule.47–53
Caregiver qualitative interviews

The authors will conduct semistructured qualitative interviews with caregivers to identify any changes that may be
required for AME delivery during HSCT and evaluate acceptability of study activities/timelines related to biological
sample collection, planned evaluations, and intervention delivery. Interviews will begin with an open-ended question to
capture overall perceptions of the caregiver’s experience (i.e.,
‘‘Please tell me about your experience of participating in the

FIG. 3. Autologous transplant
biological sample collection
timetable.
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FIG. 4. Allogeneic transplant biological sample collection timetable.
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Table 2. Measures
Variable(s)
Antecedent factors
Demographics
Parent/child age, parent
gender, SES, parent
education
Prior distress
w/hospitalization
Parent/child
Disease characteristics
Treatment characteristics
Proximal mediators
Child engagement
Parent–child interaction
Distal mediators
Family normalcy
perspective
Parent self-efficacy
Independent music play
Child outcomes
Child emotional distress
Child physical symptom
distress
(mood, anxiety, pain,
fatigue, nausea)
Child quality of life
Neurophysiological
indicator of stress
Parent outcomes
Parent emotional and
traumatic stress
symptoms
Parent distress (mood,
anxiety, fatigue)
Parent quality of life
Neurophysiological
indicator of stress
Parent/child outcomes
Family function
Qualitative interviews
Parent acceptability

No. of
items

Reliability
evidence

Family Information Form

3

N/A

T1

Parent

Prior Illness Experiences
Scale
Abbreviated PTSD
Checklist (PCL-S)
Diagnosis and Treatment
Form
Medication Data Form

13

0.78a

T1

Parent

6

0.94a

T1, T2, T3, T4

Parent

2

N/A

T4

N/A

N/A

T1, T2, T3, T4

Research
Assistant (RA)
RA

Behavioral Coding Form
Behavioral Coding Form

N/A
N/A

0.85b
85b

Sessions 2, 4, 6
Sessions 2, 4, 6

Trained Coder
Trained Coder

14

0.90a

T1, T2, T3, T4

Parent

20
2

0.85a
N/A

T1, T2, T3, T4
Sessions 2–6; T4

Parent
Parent

16

0.81a

T1, T2, T3, T4

Parent

5

0.69–0.80a

T1, T4
Sessions 2, 4, 6

Parent

20
N/A

0.89a
N/A

T1, T2, T3, T4
Appendix 5, 6

Parent
Nurse (serum);
RA (salivary)

37

0.99c

T1, T2, T3, T4

Parent

22

0.84–0.91a

T1, T2, T3, T4

Parent

3

0.69–0.80a

Parent

9
N/A

0.93a
N/A

T1, T4
Sessions 2, 4, 6
T1, T2, T3, T4
Appendix 6

30

0.90a

T1, T2, T3, T4

Parent

N/A

N/A

T4

Parent

Measure

Family Management
Measure
Family Life Difficulty
Subscale
Parental Beliefs Scale
Parent Report
CHQ—Mental Health
Subscale
Edmonton Symptom
Assessment System
KINDLR
Cortisol (serum; salivary)
Profile of Mood States-Short
Form
Impact of Events ScaleRevised (IES-R)
Edmonton Symptom
Assessment System
Index of Well-being
Cortisol (salivary)
FACES II
Parent Interview

Admin. schedule

Completed by

Parent
RA

a

Cronbach’s a.
Inter-rater reliability.
Correlation with POMS.
FACES, Family Adaptability and Cohesion Evaluation Scale; POMS, Profile of Mood States.
b
c

music play sessions with your child.’’). Follow-up questions
will include specific questions about the perceived benefit
(or nonbenefit) of AME in managing stress, experiences with
saliva collection, and the value of different intervention
components (i.e., tip sheets, goal setting worksheet, and kit
use). Interviews will occur within 2 weeks of Time 2 data
collection (in the hospital or by phone). Trained personnel, not

involved in AME delivery, will conduct audio-recorded interviews for subsequent transcription and analysis.
Data analysis plan

The following analysis includes a systematic plan to address primary and secondary aims of the proposed pilot
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study. Descriptive statistics will be computed for all variables to ensure data quality.
Research questions 1–3. Analyses will be descriptive.
The authors will report the percentage of (1) eligible caregiver/child dyads who consent to study participation (feasibility threshold = 75%) and reasons that eligible dyads
decline study participation, (2) planned intervention activities that dyads complete (acceptability threshold = 75%) and
reasons for canceled, rescheduled, and missed sessions, and
(3) planned measures that caregivers complete at Time 1,
Time 2, Time 3, and Time 4 data collections (feasibility
threshold = 75%), including examination of missing data
patterns.
Research question 4. Analyses will be descriptive. In
the first portion of these analyses, the authors will report the
percentage of cortisol samples collected from children
(feasibility threshold = 75%) and caregivers (feasibility
threshold = 85%). In the second portion, the authors will
report the proportion of samples judged to be of sufficient
quality for further analyses, such that cortisol values fall
within the range for which the assay has been validated as
well as the distribution of values collected from other
children and caregivers across the study. Given the potential for children’s samples to be altered by ingestion of food,
drink, or medication, the authors will establish a lower
feasibility threshold for children (60%) than for their
caregivers (75%).
Research question 5. The authors will use a qualitative
descriptive design with content analysis to analyze interview
data.54 Procedures include (1) interviews transcribed and
reviewed for accuracy; (2) category development through
content analysis; and (3) findings validated by peer review
to reach consensus.
Biomarker analysis plan

Assuming that the feasibility thresholds specified above are
met, blood and salivary cortisol levels will be graphed to
visualize trends.55 To complement the results of these visual
analyses, the authors will compute Tau-U statistics. The TauU statistic is a nonoverlap metric derived by comparing all
unique pairs of data points (here, cortisol levels) between the
treatment and control conditions. Before analysis, data will be
inspected for linear trends indicative of serial conditioning
effects. These effects may occur when cortisol levels measured at points in the intervention are subject to the current
and prior effects of the intervention. If conditioning effects
are detected, the calculation of the Tau-U statistic will be
adjusted for linear trends using utilities embedded in the TauU calculator. The Tau-U statistics will then be used to estimate an effect size for the treatment on levels of cortisol for
each participant and for the sample as whole.56
Discussion
Importance

Pediatric HSCT has proven to be an effective treatment
for many pediatric malignancies as well as certain nonmalignant hematologic conditions. Advances in condi-
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tioning regimens and donor options have also expanded to
populations for whom HSCT can be beneficial, including
metabolic disorders, immunodeficiencies, and even inflammatory bowel disease.57 While it is encouraging that
HSCT is a therapeutic option for increasing numbers of
otherwise incurable diseases, HSCT also raises concern
that more children and caregivers will endure significant
stress associated with the transplant and will need greater
availability and variety of supportive care options.58 AME,
as described in this protocol, not only provides support to
the child and caregiver during the acute period of HSCT
but also builds coping skills after HSCT when psychosocial
concerns such as traumatic stress symptoms emerge.59,60
Because HSCT is a complex treatment, an important aspect
of this study is to ensure that AME and study-related activities do not interfere with planned treatment protocols,
thereby avoiding creation of undo stress for the treatment
team and child–caregiver dyads. As such, this study represents an important step for refining AME for delivery
during HSCT and advancing the understanding about the
use of active music interventions to manage acute stress for
this growing patient population.
Method strength

Conventional research designs (e.g., randomized control
trials) require relatively large samples to assess treatment
effects; however, as previously noted, single-case designs
were developed for use in contexts where data can be collected from only a small number of individuals. Applying a
single-case design to the study of HSCT will allow estimation of the effects of AME on an understudied population
of children. Moreover, by collecting cortisol levels at multiple time points, it will be possible to isolate AME effects
on different aspects of HPA axis activity (i.e., waking cortisol levels, baseline levels, or diurnal cortisol throughout
the day) by comparing levels of cortisol that correspond to
different aspects of HPA axis activity on treatment and
control days. Additionally, hospitalization will provide a
controlled environment where medical records can be used
to identify events that may contribute to unexpected fluctuations in cortisol levels, allowing for more accurate data
interpretation.
Potential limitations

For children with malignant disease requiring HSCT,
there may be long-term effects of therapy on the HPA
axis.29,61–63 This may create difficulties in interpretation of
patient cortisol levels and the potential clinical benefit of
AME. Collection of baseline cortisol may be useful in differentiating between long-term treatment effects and the
effects of AME. Additionally, HSCT-related side effects,
such as pain associated with mucositis or general malaise,
might result in patients choosing not to provide a biological
sample. Finally, the inability of consenting caregivers to be
present for all AME sessions and saliva collections due to
work or other caregiver responsibilities may result in missed
collections.
This study will provide important information about the
feasibility/acceptability of collecting cortisol samples at the
frequency required for single-case design from young
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children and caregivers during a high-risk high-intensity
treatment. In addition, findings will advance the understanding about the use of active music interventions to
mitigate the inter-related distress experienced by children
and caregivers during the transplant period.
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